GRAIL to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

GRALV 11.04.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-21
Name of Upcoming Event:Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Full Press ReleaseSEC FilingsOur GRALV Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Patient Reported Outcomes for GRAIL's Galleri® Multi-Cancer Early Detection Blood Test Published in Lancet Oncology
  • 12.18.2024 - GRAIL to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

    MENLO PARK, Calif.,Nov. 4, 2024/PRNewswire/ --GRAIL, Inc.(Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Canaccord Genuity MedTech, Diagnostics andDigital Health & Services ForuminNew YorkonThursday, Nov. 21at11:00 a.m. ET.

    GRAIL, Inc. is a healthcare company whose mission is to detect cancer early when it can be cured. (PRNewsfoto/GRAIL, Inc.)

    Live and replay webcasts may be accessed in the investor relations section of GRAIL's website atinvestors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.

    About GRAILGRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered inMenlo Park, CAwith locations inWashington, D.C.,North Carolina, and theUnited Kingdom.For more information, visitgrail.com.

    CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-present-at-the-canaccord-genuity-medtech-diagnostics-and-digital-health--services-forum-302295742.html

    SOURCEGRAIL, Inc.

    Corporate Communications: Kristen Davis, Trish Rowland, pr@grail.com; Investor Relations: Alex Dobbin, Alexis Tosti, ir@grail.com

    Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com